

Antibiotics – Inhaled aztreonam

Medical policy no. 16.14.00-1

Effective Date: July 1, 2018

Related medical policies:

- Antibiotics – Inhaled aminoglycosides

Medical necessity

Drug	Medical Necessity
aztreonam (CAYSTON®)	<p>Cayston® may be considered medically necessary when: Used to treat patients with cystic fibrosis (CF) known to have <i>Pseudomonas aeruginosa</i> in the lungs</p> <ul style="list-style-type: none"> • Non-preferred product requires trial of a preferred inhaled aminoglycoside

Clinical policy:

Drug	Clinical Criteria (Initial Approval)
aztreonam (CAYSTON®)	<p>Cayston® may be covered when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of cystic fibrosis (CF) 2. Positive culture for <i>Pseudomonas aeruginosa</i> infection in the lungs 3. NONE of the following: <ol style="list-style-type: none"> a. Less than (<) 7 years of age b. FEV₁ less than (<) 25% or greater than (>) 75% predicted c. Positive colonization with <i>Burkholderia cepacia</i> <p>Approve for 12 months</p>
	Criteria (Reauthorization)
	<p>Documentation of positive clinical response</p> <p>Approve for 12 months</p>

Dosage and quantity limits

Drug Name	Dose and Quantity Limits
Aztreonam (CAYSTON®)	84mL (56 ampules) per 28-days

References

1. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. [cited 2016 Dec 19]. Available: <https://www.guideline.gov>.
2. Cayston [package insert]. Foster City, CA: Gilead Sciences Inc; 2014.